We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

New Rapid Diagnostic Test to Tackle Fatal Sleeping Sickness

By LabMedica International staff writers
Posted on 27 Jan 2016
Print article
Image: The bite of an infected female tsetse fly taking a bloodmeal can transmit Trypanosoma brucei gambiense, cause of Human African Trypanosomiasis (HAT), also called African sleeping sickness, usually fatal if untreated  with patients falling into a coma before death (Photo David Bygott/Flickr, courtesy of Biotechnology and Biological Sciences Research Council (UK)).
Image: The bite of an infected female tsetse fly taking a bloodmeal can transmit Trypanosoma brucei gambiense, cause of Human African Trypanosomiasis (HAT), also called African sleeping sickness, usually fatal if untreated with patients falling into a coma before death (Photo David Bygott/Flickr, courtesy of Biotechnology and Biological Sciences Research Council (UK)).
Using an innovative approach, scientists have developed a simple serodiagnostic method, similar to a dipstick pregnancy test, to fight human African trypanosomiasis (HAT) caused by Trypanosoma brucei gambiense. The new test requires only a pin-prick blood sample and will remove the need to take complex equipment into remote areas.

Although millions are at risk of contracting HAT, some at-risk areas remain uncovered by surveillance and control efforts. Existing tests for T. b. gambiense rely on samples extracted directly from this dangerous parasite. A research team, led by Dr Barrie Rooney and Prof. Mark Smales of the University of Kent (Kent, UK), has designed a safer, easier, faster (about half the time of traditional methods), and less costly method for preparing samples. Also, fewer people will be needed to administer the test.

This next-generation test is based on genetic engineering to express selected T.b. gambiense recombinant antigens in a safe, easy-to-grow strain of the non-human parasite Leishmania tarentolae.

The work is part of the Biotechnology and Biological Sciences Research Council (BBSRC)’s Flexible Interchange Program (FLIP) in a project with Medecins Sans Frontieres (MSF; Geneva, Switzerland). Dr Rooney said: “I have been involved with MSF mobile HAT screening teams in central African countries for over 10 years. Traditional testing involves a large team in remote areas doing time-consuming microscopic work, and painful lumbar punctures. For this you need electricity and refrigeration. By combining the latest genome databases and old fashioned fermentation techniques we have come up with a fast, simple way of making robust and reliable tests. The new tests are designed to be heat-stable and user-friendly, like a dipstick pregnancy test. It will be a major improvement for screening and treatment of this deadly disease and speed us on the way to ‘the elimination of sleeping sickness as a public health hazard’ which is a World Health Organization target.”

Prof. Melanie Welham, executive director, BBSRC, Science, said, “This is a brilliant example of exactly what the FLIP scheme is all about. FLIP funding allowed Dr Rooney to work with the University of Kent and MSF to design and develop this test in just 14 months. The promise and potential impact of this new diagnostic is obvious and I wish Dr Rooney success in the forthcoming work in the Democratic Republic of the Congo (DRC). FLIP brings scientists into different environments where they can learn new skills and exploit their existing expertise in new collaborations, enhancing the impact of bioscience research.”

In July, Dr Rooney traveled to DRC to identify areas where field trials of the new test could be carried out, alongside an MSF HAT mobile team. The method also has potential to be developed for diagnosis of other tropical diseases, such as Chagas disease (T. cruzi) and visceral leishmaniasis.

The study, by Rooney B et al., was published December, 2015, in the journal PLOS Neglected Tropical Diseases.

Related Links:

University of Kent
Biotechnology and Biological Sciences Research Council (BBSRC) 
Medecins Sans Frontieres

Gold Supplier
Automated, Random Access Chemistry Analyzer
LIDA 300
3 Part Diff Auto Hematology Analyzer
Herpes Simplex Virus Test
S3002E HSV-2

Print article


Clinical Chem.

view channel
Image: Electrochemical cells etched by laser on wooden tongue depressor measure glucose and nitrite in saliva (Photo courtesy of Analytical Chemistry)

Biosensor-Fabricated Wooden Tongue Depressor Measures Glucose and Nitrite in Saliva

Physicians often use tongue depressors to examine a patient's mouth and throat. However, it is hard to imagine that this simple wooden tool could actively assess a patient's health. This idea has led to... Read more


view channel
Image: The Atellica HEMA 570 and 580 hematology analyzers remove workflow barriers (Photo courtesy of Siemens)

Next-Gen Hematology Analyzers Eliminate Workflow Roadblocks and Achieve Fast Throughput

Hematology testing is a critical aspect of patient care, utilized to establish a patient's health baseline, track treatment progress, or guide timely modifications to care. However, increasing constraints... Read more


view channel
Image: Newly observed anti-FSP antibodies have also been found to predict immune-related adverse events (Photo courtesy of Calviri)

First Blood-Based Biomarkers Test to Predict Treatment Response in Cancer Patients

Every year worldwide, lung cancer afflicts over two million individuals and almost the same number of people succumb to the disease. This malignancy leads the charts in cancer-related mortalities, with... Read more


view channel
Image: The UNIQO 160 (CE-IVDR) advances diagnostic analysis for autoimmune diseases (Photo courtesy of EUROIMMUN)

Novel Automated IIFT System Enables Cutting-Edge Diagnostic Analysis

A newly-launched automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics offers an all-in-one solution to enhance the efficiency of the complete IIFT process, comprising... Read more


view channel
Electronic biosensor uses DNA aptamers for detecting biomarkers in whole blood samples (Photo courtesy of Freepik)

Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents

The absence of robust, reliable, and user-friendly bioanalytical tools for early and timely diagnosis of cardiovascular diseases, particularly sudden cardiac arrest, leads to preventable deaths and imposes... Read more


view channel
Image: The global HbA1c testing devices market is expected to reach USD 2.56 billion in 2027 (Photo courtesy of Freepik)

Global Hemoglobin A1c Testing Devices Market Driven by Rising Prevalence of Diabetes

Hemoglobin A1c (HbA1c), or glycated hemoglobin, refers to hemoglobin with glucose attached. HbA1c testing devices are used for blood tests that determine average blood glucose, or blood sugar levels.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.